focus -WSS

focus

author：focus 2025-09-30 00:36:06 - browse：15787

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Female surgeons have lower rates of long

explore

WSS

Wellcome Trust names Røttingen as its new CEO

Readout Newsletter: XBI biotech index, Akero Therapeutics

Diversifying clinical trials isn't enough to close racial gaps: study

Akero's treatment for NASH falls short in cirrhosis study

Readout Newsletter: What happened with Sarepta's Duchenne data

WHO may add ‘noma' to its list of neglected tropical diseases

leisure time

focus

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

Life sciences deals on track to hit lowest point since 2017

Affirmative action in medical school literally saved lives

A fraught question for the kids of Alzheimer’s: Is it coming for us?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Senate panel to vote on hospitals, PBMs, prisoner care

Sports medicine is finally prioritizing gender equality

Medicare to cover more brain scans related to Alzheimer’s drugs

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: What happened with Sarepta's Duchenne data

hotspot

Eight reasons why you should get an updated Covid vaccine

European regulators consider appeal over Amylyx ALS drug

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Eight reasons why you should get an updated Covid vaccine

Eli Lilly to pay $200M for Beam’s stake in gene

explore

hotspot

explore

focus